GENE ONLINE|News &
Opinion
Blog

2020-08-31| In-DepthR&DSpecial

Spotlight: Infusion-Related Reactions Associated with Rapid Infusion of Daratumumab

by GeneOnline
Share To
Daratumumab, an anti-CD38 monoclonal antibody, has revolutionized the treatment outcome and prognostic expectations in patients with relapsed myeloma. The USFDA approved it in November 2015 for treating patients with relapsed refractory multiple myeloma (RRMM) and those with newly diagnosed multiple myeloma (MM) who are ineligible for stem cell transplant.

Daratumumab, as the newest class of therapeutics for MM, has demonstrated substantial clinical efficacy and rapid and durable response in patients with RRMM who relapse after initial therapy or are refractory to immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) [1,2].

GO Prime with only $1.49 now

LATEST
Repairing Genetic Mutations in Neurological Diseases with RNA Targeting Strategy
2022-11-25
AstraZeneca Thailand Wins Two ACES Awards 2022: “Industry Champions of the Year” and “Community Initiative”
2022-11-24
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
2022-11-24
Novartis Shifts Gear To Phase 3 For Anti-Malaria Drug
2022-11-24
Moving Past Animal Models with Better Data for Drug Discovery
2022-11-23
IonOpticks ushers in a new age of proteomics with Aurora Frontier
2022-11-23
Korea Ginseng Corp.: As an adaptogenic herb, Korean red ginseng boosts the human immune response
2022-11-23
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!